Norbert G. Riedel, Ph.D. - President & Chief Executive Officer

Norbert G. Riedel, Ph.D.

President & Chief Executive Officer

Dr. Riedel is president and chief executive officer at Naurex, as well as member of the board of directors. He was formerly corporate vice president and chief science and innovation officer at Baxter International. Earlier in his tenure at Baxter, Dr. Riedel was president and general manager of the recombinant proteins unit and vice president of research and development for Baxter’s bioscience business. Previously, Dr. Riedel was head of worldwide biotechnology and core research functions and held a number of scientific management positions at Hoechst Marion Roussel, now Sanofi. Dr. Riedel serves on the boards of Jazz Pharmaceuticals, Ariad Pharmaceuticals and the Illinois Biotechnology Industry Organization. Dr. Riedel is a member of the Austrian Academy of Sciences and was appointed by Governor Pat Quinn to serve on the Illinois Innovation Council. Dr. Riedel received a Diploma and Ph.D. from the University of Frankfurt and was a postdoctoral fellow at Harvard University and a visiting professor at the Massachusetts Institute of Technology.

Joseph R. Moskal, Ph.D. - Founder & Chief Scientific Officer

Joseph R. Moskal, Ph.D.

Founder & Chief Scientific Officer

Dr. Moskal is the founder of Naurex and chief scientific officer. He is also director of the Falk Center for Molecular Therapeutics and distinguished professor of biomedical engineering at Northwestern University. Dr. Moskal previously served as assistant professor and director of the neurosurgery laboratories at the Albert Einstein College of Medicine. Earlier, he was a staff fellow at the National Institutes of Health in the laboratories of Nobel laureates Marshall Nirenberg and Julius Axelrod. Dr. Moskal is well known for his research on the NMDA receptor. He discovered Naurex’s lead molecule, rapastinel (GLYX-13), and also discovered NRX-1074 in conjunction with Dr. Amin Khan. He received a B.S. and a Ph.D. from the University of Notre Dame.

Ronald M. Burch, M.D., Ph.D. - Chief Medical Officer

Ronald M. Burch, M.D., Ph.D.

Chief Medical Officer

Dr. Burch is chief medical officer at Naurex. Dr. Burch has more than 20 years’ experience in various aspects of discovery research, drug development, regulatory affairs and new product assessment, including working on two NMDAR drug development programs. He has developed a number of CNS programs through successful product registration. Dr. Burch was previously founder and chief executive officer of Biowave Corp., AlgoRx Pharmaceuticals and Cure Therapeutics, and has held senior positions at Pacira Pharmaceuticals, Purdue Pharma, Zeneca, Rhone Poulenc-Rorer, Nova Pharmaceutical Corp., and the National Institutes of Health. Dr. Burch received B.S. degrees in chemistry and marine biology from the College of Charleston, as well as a Ph.D. in pharmacology and an M.D. from the Medical University of South Carolina. He served as a medical staff fellow at the National Institutes of Health in the laboratory of Nobel laureate Julius Axelrod.

James Schulz - Chief Financial Officer

James Schulz

Chief Financial Officer

Mr. Schulz is chief financial officer at Naurex. He was formerly a partner at Upward Focus, LLC, which later merged its practice into Milestone Advisors, LLC, where he operated as the chief financial officer for small medical device and pharmaceutical start-up companies. Prior to this, Mr. Schulz served as director of finance at Suros Surgical Systems, where he implemented operational and financial improvements and assisted in the company’s acquisition by Hologic, Inc. Prior to Suros, Mr. Schulz served in a number of financial and operational roles at Eli Lilly & Co. He began his career working with a variety of clients as an accountant at Ernst & Young. Mr. Schulz received a B.S. from Indiana University, Bloomington and is a licensed C.P.A.

Patty Adams - Vice President, Human Resources

Patty Adams

Vice President, Human Resources

Ms. Adams is vice president of human resources at Naurex. She has over 24 years of experience in the healthcare industry which includes 15 years in human resources. Prior to joining Naurex she served as the senior director of human resources for Durata Therapeutics where she managed HR planning and operations in support of the commercial launch of Dalvance®. Ms. Adams has also led human resources functions at SagePath Medical, BioSante Pharmaceuticals, and Lundbeck Inc. Previously, Ms. Adams was employed by Takeda Pharmaceuticals North America for 11 years where she held positions of increasing responsibility in both human resources and sales administration. Ms. Adams earned a B.A. in psychology from Columbia College and a M.S. degree in human resources from Loyola University Chicago.

David R. Houck, Ph.D. - Vice President, Drug Development Operations & Quality

David R. Houck, PhD

Vice President, Drug Development Operations & Quality

Dr. Houck is vice president of drug development operations and quality at Naurex. He has over 35 years of experience in the pharmaceutical and biotechnology industries in formulation development, manufacture, and quality control of new chemical entities. Most recently, Dr. Houck was chief executive officer at Pharmakey LLC, a provider of regulatory, CMC, preclinical, and translational medicine services to biopharmaceutical companies. Previously, he held senior positions at Merck, Sanofi, OSI Pharmaceuticals, and Scynexis. Dr. Houck has authored or co-authored over 30 articles and is an inventor on more than 10 patents. He received a B.S. degree from Alma College, an M.S. degree from Purdue University, a Ph.D. from Ohio State University, and served as a postdoctoral fellow in the Los Alamos National Laboratory.

M. Amin Khan, Ph.D. - Vice President, Chemistry R&D

M. Amin Khan, PhD

Vice President, Chemistry R&D

Dr. Khan is vice president of chemistry research and development at Naurex. He has over 20 years’ experience as a senior chemist at several biotechnology companies, including Elan and Gliatech. Dr. Khan discovered and developed multiple novel CNS molecules that have entered human clinical trials including NRX-1074 and other Naurex NMDA receptor modulators in conjunction with Dr. Joseph Moskal. Dr. Khan holds a B.S. and B.Ed. from the Regional Institute of Education, Bhopal, India, and M.S. and Ph.D. degrees from Kanpur University in India. He was a postdoctoral fellow at the Indian Institute of Technology, Kanpur, India.

Ashish Khanna - Vice President, Corporate Development

Ashish Khanna

Vice President, Corporate Development

Mr. Khanna is vice president of corporate development at Naurex. He previously served as director of business development at Vanda Pharmaceuticals where he managed multiple transactions including the company’s $400+ million partnership with Novartis on Fanapt® for the treatment of schizophrenia. Mr. Khanna was formerly a member of the cardiology strategic marketing team at Cordis Corporation, a Johnson & Johnson company. Earlier in his career, he was a strategy consultant with the Palladium Group and with the Strategic Advisory Services practice of Ernst & Young (now Capgemini). Mr. Khanna holds a B.S. in finance and B.A.S. in systems engineering from the University of Pennsylvania, as well as an M.B.A. from the Wharton School.